← boothcheck

CME vs MS stock comparison

CME GROUP INC. vs MORGAN STANLEY, two Financial Services stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.

CME Group is a toll-taker on derivatives volume, and the margins show it: 63.19% of revenue becomes net income, with no debt on the books and a 5.39% free-cash yield feeding a 2.26% dividend. It trades at 18.86 times earnings and 3.02 times book. Morgan Stanley earns across trading, advisory, and wealth management at a 24.65% net margin, leans on 3.15 debt-to-equity, and returns 15.7% on equity. On price the two nearly rhyme: 18.86 times earnings against 19.21 times, 3.02 times book against 2.90. The exchange keeps a far larger slice of each dollar; the bank makes it up in scale and diversity of desks.

Comparison updated 2026-07-11.

CME vs MS: the numbers

MetricCMEMS
Price$240.29$222.17
Market cap$87.3B$350.1B
SectorFinancial ServicesFinancial Services
StageMatureGrowth
Implied growth (priced in)+5.0%
P/E20.520.1
P/B3.283.03
P/S12.914.76
EV/EBITDA18.7811.8
Revenue growth+7.5%+14.1%
Operating margin69.7%
Net margin63.2%24.6%
Return on equity16.0%15.7%
Return on assets2.1%1.1%
Dividend yield2.1%1.7%
Debt / equity0.003.15
Current ratio1.02
Altman Z (solvency)0.410.30
Piotroski F (quality)8 / 97 / 9
Full CME report → Full MS report →
Get boothcheck's read on CME and MS, and what their prices are betting on, in your inbox. No hype, no spam.
Free. Informational only, not investment advice. Unsubscribe anytime.

Compare any two stocks

vs

The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.